{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nRecent investigations into proteins with zinc finger motifs and TRAF-like domains have hinted at a role in modulating cellular signaling pathways critical to oncogenesis. Although ZFTRAF1 itself has not been extensively characterized, studies evaluating related proteins such as CYHR1—involved in interactions with murine galectin-3—have begun to shed light on potential roles in tumor progression, cell adhesion, and intracellular communication. These findings, derived from research on esophageal cancer models, suggest that proteins sharing features with ZFTRAF1 may influence tumor behavior and patient outcomes."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "Neurodevelopmental disorders, known for their clinical and genetic heterogeneity, have been linked to dysfunctions in a variety of cellular pathways. Although the precise mechanisms remain to be fully delineated, it is conceivable that proteins like ZFTRAF1—with structural elements that enable interactions across diverse signaling networks—could contribute to neural development and its disorders. Such insights point to the possibility that perturbations in the function of these multifaceted proteins may underlie aspects of neurodevelopmental pathomechanisms."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "Collectively, these emerging lines of evidence underscore the versatile roles of zinc finger proteins, including the putative functions of ZFTRAF1, in both cancer biology and neurodevelopment. The modulation of pathways ranging from galectin-associated signaling in esophageal cancer to the diverse intracellular cascades implicated in neurodevelopmental disorders invites further investigation. A deeper understanding of ZFTRAF1’s molecular interactions may ultimately pave the way for targeted therapeutic strategies in oncology and neuropsychiatric conditions."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Ryosuke Desaki, Genta Sawada, Hiroshi Okumura, et al. "}, {"type": "b", "children": [{"type": "t", "text": "As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Ann Surg Oncol (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1245/s10434-015-5031-0"}], "href": "https://doi.org/10.1245/s10434-015-5031-0"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26676980"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26676980"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Maria Asif, Arwa Ishaq A Khayyat, Salem Alawbathani, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Biallelic loss-of-function variants of ZFTRAF1 cause neurodevelopmental disorder with microcephaly and hypotonia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Genet Med (2024)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.gim.2024.101143"}], "href": "https://doi.org/10.1016/j.gim.2024.101143"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "38641995"}], "href": "https://pubmed.ncbi.nlm.nih.gov/38641995"}]}]}]}